L-精氨酸与L-瓜氨酸用于子痫前期预防和治疗:系统评价与Meta分析
该系统评价与Meta分析纳入20项随机对照试验(2028名女性)和3项非随机试验(189名女性),评估L-精氨酸和L-瓜氨酸对子痫前期的预防与治疗作用。预防性试验中,L-精氨酸与子痫前期风险降低相关(RR 0.52;95%CI 0.35,0.78;低确定性证据,4项试验)及重度子痫前期风险降低相关(RR 0.23;95%CI 0.09,0.55;低确定性证据,3项试验)。治疗性试验中,L-精氨酸可能降低平均收缩压(MD -5.64 mmHg;95%CI -10.66,-0.62;极低确定性证据,3项试验)和胎儿生长受限风险(RR 0.46;95%CI 0.26,0.81;低确定性证据,2项试验)。仅一项研究(36名女性)考察L-瓜氨酸,报告对子痫前期或血压无影响。
要点
- 预防性使用L-精氨酸与子痫前期风险降低相关(RR 0.52;95%CI 0.35,0.78;低确定性证据)。
- 治疗性使用L-精氨酸可能降低平均收缩压(MD -5.64 mmHg;95%CI -10.66,-0.62;极低确定性证据)。
- 需更多试验确定补充的最佳剂量和开始时间以支持临床决策。
核心结论
- L-精氨酸可能对子痫前期的预防和治疗有前景,但应谨慎解读结果。
- 需要更多试验确定补充的最佳剂量和开始时间以支持临床决策。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、Embase、CINAHL、Global Index Medicus和Cochrane Library截至2024年2月7日。
- 纳入20项随机对照试验(2028名女性)和3项非随机试验(189名女性),比较L-精氨酸或L-瓜氨酸与安慰剂或标准治疗。
- 预防性试验和治疗性试验分别采用随机效应模型进行Meta分析。
主要发现
- 预防性试验中,L-精氨酸与子痫前期风险降低相关(RR 0.52;95%CI 0.35,0.78;低确定性证据,4项试验)。
- 预防性试验中,L-精氨酸与重度子痫前期风险降低相关(RR 0.23;95%CI 0.09,0.55;低确定性证据,3项试验)。
- 治疗性试验中,L-精氨酸可能降低平均收缩压(MD -5.64 mmHg;95%CI -10.66,-0.62;极低确定性证据,3项试验)。
- 治疗性试验中,L-精氨酸可能降低胎儿生长受限风险(RR 0.46;95%CI 0.26,0.81;低确定性证据,2项试验)。
- 仅一项研究(36名女性)考察L-瓜氨酸,报告对子痫前期或血压无影响。
临床怎么用
- 作者认为L-精氨酸可能对子痫前期的预防和治疗有前景,但应谨慎解读结果。
- 作者指出需要更多试验确定补充的最佳剂量和开始时间以支持临床决策。
局限性
- 8项随机对照试验的偏倚风险为「高」,12项显示「一些担忧」。
- L-精氨酸预防子痫前期的证据确定性为低(4项试验)。
- L-精氨酸预防重度子痫前期的证据确定性为低(3项试验)。
- L-精氨酸降低平均收缩压的证据确定性为极低(3项试验)。
- L-精氨酸降低胎儿生长受限的证据确定性为低(2项试验)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence suggests L-arginine may be effective at reducing pre-eclampsia and related outcomes. However, whether L-arginine can prevent or only treat pre-eclampsia, and thus the target population and timing of initiation, remains unknown. OBJECTIVES: To evaluate the effects of L-arginine and L-citrulline (precursor of L-arginine) on the prevention and treatment of pre-eclampsia. SEARCH STRATEGY: MEDLINE, Embase, CINAHL, Global Index Medicus and the Cochrane Library were searched through 7 February 2024. SELECTION CRITERIA: Trials administering L-arginine or L-citrulline to pregnant women, with the comparison group receiving placebo or standard care, were included. DATA COLLECTION AND ANALYSIS: Meta-analyses were conducted separately for prevention or treatment trials, using random-effects models. MAIN RESULTS: Twenty randomised controlled trials (RCTs) (2028 women) and three non-randomised trials (189 women) were included. The risk of bias was 'high' in eight RCTs and showed 'some concerns' in 12. In prevention trials, L-arginine was associated with a reduced risk of pre-eclampsia (relative risk [RR] 0.52; 95% confidence interval [CI], 0.35, 0.78; low-certainty evidence, four trials) and severe pre-eclampsia (RR 0.23; 95% CI, 0.09, 0.55; low-certainty evidence, three trials). In treatment trials, L-arginine may reduce mean systolic blood pressure (MD -5.64 mmHg; 95% CI, -10.66, -0.62; very low-certainty evidence, three trials) and fetal growth restriction (RR 0.46; 95% CI, 0.26, 0.81; low-certainty evidence, two trials). Only one study (36 women) examined L-citrulline and reported no effect on pre-eclampsia or blood pressure. CONCLUSIONS: L-arginine may be promising for pre-eclampsia prevention and treatment, but findings should be interpreted cautiously. More trials are needed to determine the optimal dose and time to commence supplementation and support clinical decision-making.
引用
- Makama M, McDougall ARA, Cao J, et al. L-Arginine and L-Citrulline for Prevention and Treatment of Pre-Eclampsia: A Systematic Review and Meta-Analysis. BJOG. 2025. PMID: 39800868. doi:10.1111/1471-0528.18070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。